Evan Martin Bloch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Evan Martin Bloch has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Roberta Bruhn
Vitalant Research Institute San Francisco California USA
3 shared publications Edward L. Murphy
Blood Systems Research Institute
2 shared publicationsLeilani Montalvo
Blood Systems Research Institute (BSRI); San Francisco, CA, USA
2 shared publicationsLisa Barcellos
University of California Berkeley; Division of Epidemiology; School of Public Health; Berkeley, CA USA
2 shared publicationsMichael P. Busch
Blood Systems Research Institute San Francisco California
2 shared publicationsStephen Shiboski
University of California San Francisco; Department of Epidemiology and Biostatistics; San Francisco, CA, USA
2 shared publications
Latest Publications
- 28 October 2015
- Published by Wiley in Transfusion
- Vol. 56 (2) , 457-465
A retrospective analysis of false‐positive infectious screening results in blood donors
BACKGROUND: False‐positive infectious transfusion screening results remain a challenge with continued loss of both donors and blood products. We sought to identify associations between donor demographic characteristics (age, race, sex, education, first‐time donor status) and testing false positive for viruses during routine blood donation screening. In addition the study assessed the prevalence of high‐risk behaviors in false‐positive donors.STUDY DESIGN AND METHODS: Blood Systems, Inc. donors with allogeneic donations between January 1, 2011, and December 31, 2012, were compared in a case‐control study. Those with a false‐positive donation for one of four viruses (human immunodeficiency virus [HIV], human T‐lymphotropic virus [HTLV], hepatitis B virus [HBV], and hepatitis C virus [HCV]) were included as cases. Those with negative test results were controls. For a subset of cases, infectious risk factors were evaluated.RESULTS: Black race and Hispanic ethnicity were associated with HCV and HTLV false‐positive results. Male sex and lower education were associated with HCV false positivity, and age 25 to 44 was associated with HTLV false positivity. First‐time donors were more likely to be HCV false positive although less likely to be HBV and HTLV false positive. No significant associations between donor demographics and HIV false positivity were observed. A questionnaire for false‐positive donors showed low levels of high‐risk behaviors.CONCLUSION: Demographic associations with HCV and HTLV false‐positive results overlap with those of true infection. While true infection is unlikely given current testing algorithms and risk factor evaluation, the findings suggest nonrandom association. Further investigation into biologic mechanisms is warranted.
- 28 October 2015
- Published by Wiley in Transfusion
- Vol. 56 (2) , 457-465
A retrospective analysis of false‐positive infectious screening results in blood donors
BACKGROUND: False‐positive infectious transfusion screening results remain a challenge with continued loss of both donors and blood products. We sought to identify associations between donor demographic characteristics (age, race, sex, education, first‐time donor status) and testing false positive for viruses during routine blood donation screening. In addition the study assessed the prevalence of high‐risk behaviors in false‐positive donors.STUDY DESIGN AND METHODS: Blood Systems, Inc. donors with allogeneic donations between January 1, 2011, and December 31, 2012, were compared in a case‐control study. Those with a false‐positive donation for one of four viruses (human immunodeficiency virus [HIV], human T‐lymphotropic virus [HTLV], hepatitis B virus [HBV], and hepatitis C virus [HCV]) were included as cases. Those with negative test results were controls. For a subset of cases, infectious risk factors were evaluated.RESULTS: Black race and Hispanic ethnicity were associated with HCV and HTLV false‐positive results. Male sex and lower education were associated with HCV false positivity, and age 25 to 44 was associated with HTLV false positivity. First‐time donors were more likely to be HCV false positive although less likely to be HBV and HTLV false positive. No significant associations between donor demographics and HIV false positivity were observed. A questionnaire for false‐positive donors showed low levels of high‐risk behaviors.CONCLUSION: Demographic associations with HCV and HTLV false‐positive results overlap with those of true infection. While true infection is unlikely given current testing algorithms and risk factor evaluation, the findings suggest nonrandom association. Further investigation into biologic mechanisms is warranted.
- 16 March 2015
- Published by Wiley in Transfusion
- Vol. 55 (7) , 1675-1684
The impact of human immunodeficiency virus infection on obstetric hemorrhage and blood transfusion in South Africa
BACKGROUND: Globally, as in South Africa, obstetric hemorrhage (OH) remains a leading cause of maternal mortality and morbidity. Although blood transfusion is critical to OH management, the incidence and predictors of transfusion as well as their relation to human immunodeficiency virus (HIV) infection are poorly described.STUDY DESIGN AND METHODS: A cross‐sectional study was conducted of all peripartum patients at four major hospitals in South Africa (April to July 2012). Comprehensive clinical data were collected on patients who sustained OH and/or were transfused. Logistic regression was used to model risk factors for OH and transfusion.RESULTS: A total of 15,725 peripartum women were evaluated, of whom 3969 (25.2%) were HIV positive. Overall, 387 (2.5%) women sustained OH and 438 (2.8%) received transfusions, including 213 (1.4%) women with both OH and transfusion. There was no significant difference in OH incidence between HIV‐positive (2.8%) and HIV‐negative (2.3%) patients (adjusted odds ratio [OR], 0.95; 95% confidence interval [CI], 0.72‐1.25). In contrast, the incidence of blood transfusion was significantly higher in HIV‐positive (3.7%) than in HIV‐negative (2.4%) patients (adjusted OR, 1.52; 95% CI, 1.14‐2.03). Other risk factors for transfusion included OH, low prenatal hemoglobin, the treating hospital, lack of prenatal care, and gestational age of not more than 34 weeks.CONCLUSION: In the South African obstetric setting, the incidence of peripartum blood transfusion is significantly higher than in the United States and other high‐income countries while OH incidence is similar. While OH and prenatal anemia are major predictors of transfusion, HIV infection is a common and independent contributing factor.
- 16 March 2015
- Published by Wiley in Transfusion
- Vol. 55 (7) , 1675-1684
The impact of human immunodeficiency virus infection on obstetric hemorrhage and blood transfusion in South Africa
BACKGROUND: Globally, as in South Africa, obstetric hemorrhage (OH) remains a leading cause of maternal mortality and morbidity. Although blood transfusion is critical to OH management, the incidence and predictors of transfusion as well as their relation to human immunodeficiency virus (HIV) infection are poorly described.STUDY DESIGN AND METHODS: A cross‐sectional study was conducted of all peripartum patients at four major hospitals in South Africa (April to July 2012). Comprehensive clinical data were collected on patients who sustained OH and/or were transfused. Logistic regression was used to model risk factors for OH and transfusion.RESULTS: A total of 15,725 peripartum women were evaluated, of whom 3969 (25.2%) were HIV positive. Overall, 387 (2.5%) women sustained OH and 438 (2.8%) received transfusions, including 213 (1.4%) women with both OH and transfusion. There was no significant difference in OH incidence between HIV‐positive (2.8%) and HIV‐negative (2.3%) patients (adjusted odds ratio [OR], 0.95; 95% confidence interval [CI], 0.72‐1.25). In contrast, the incidence of blood transfusion was significantly higher in HIV‐positive (3.7%) than in HIV‐negative (2.4%) patients (adjusted OR, 1.52; 95% CI, 1.14‐2.03). Other risk factors for transfusion included OH, low prenatal hemoglobin, the treating hospital, lack of prenatal care, and gestational age of not more than 34 weeks.CONCLUSION: In the South African obstetric setting, the incidence of peripartum blood transfusion is significantly higher than in the United States and other high‐income countries while OH incidence is similar. While OH and prenatal anemia are major predictors of transfusion, HIV infection is a common and independent contributing factor.
- Open Access
- 15 February 2015
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 15 (1) , 63
Demographic determinants of syphilis seroprevalence among U.S. blood donors, 2011–2012
No cases of transfusion-transmitted syphilis have been described for over four decades. While there is mandatory transfusion screening for syphilis, the absence of transmission is in part ascribed to a low prevalence of syphilis in the blood donor population, the concomitant use of antibiotics in a high proportion of transfusion recipients, allied with poor survival of T. pallidum during refrigerated storage of blood products. A cross-sectional retrospective data analysis was conducted to ascertain the prevalence of Treponema pallidum antibodies in U.S. blood donors by demography and geography. Routine blood donation testing data and demographics were extracted from the data warehouse of a large network of U.S. blood centers. Crude and adjusted prevalence of T. pallidum antibodies and active syphilis infection were calculated, and GIS mapping was used to illustrate geographic distribution. The prevalence of T. pallidum seropositivity and active syphilis in first time donors was 162.6 (95% CI 145.5-181.2) per 100,000 donors and 15.8 (95% CI 10.8-22.3) per 100,000 donors, respectively. The odds of T. pallidum seropositivity were significantly elevated in African American (OR = 18.9, 95% CI 14.2-25.2), and Hispanic (OR = 2.8, 95% CI 2.0-3.8) as compared to Caucasian donors. Similarly, the odds of active T. pallidum infections were significantly higher in African American (OR 15.0, 95% CI 7.0-32.3) and Hispanic (OR = 5.8, 95% CI 2.9-11.6) as compared to Caucasian donors. Syphilis seropositivity was associated with first time blood donation, increasing age, lower education, birth outside the US, and positive tests for HIV and HCV. Geographically, T. pallidum seropositivity was increased in southern and western regions of the US. Given the low seroprevalence of syphilis in blood donors, continued screening remains debatable; however it may provide a public health benefit through surveillance of at-risk populations.
- 15 February 2015
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 15 (1) , 63
Open AccessDemographic determinants of syphilis seroprevalence among U.S. blood donors, 2011–2012
No cases of transfusion-transmitted syphilis have been described for over four decades. While there is mandatory transfusion screening for syphilis, the absence of transmission is in part ascribed to a low prevalence of syphilis in the blood donor population, the concomitant use of antibiotics in a high proportion of transfusion recipients, allied with poor survival of T. pallidum during refrigerated storage of blood products. A cross-sectional retrospective data analysis was conducted to ascertain the prevalence of Treponema pallidum antibodies in U.S. blood donors by demography and geography. Routine blood donation testing data and demographics were extracted from the data warehouse of a large network of U.S. blood centers. Crude and adjusted prevalence of T. pallidum antibodies and active syphilis infection were calculated, and GIS mapping was used to illustrate geographic distribution. The prevalence of T. pallidum seropositivity and active syphilis in first time donors was 162.6 (95% CI 145.5-181.2) per 100,000 donors and 15.8 (95% CI 10.8-22.3) per 100,000 donors, respectively. The odds of T. pallidum seropositivity were significantly elevated in African American (OR = 18.9, 95% CI 14.2-25.2), and Hispanic (OR = 2.8, 95% CI 2.0-3.8) as compared to Caucasian donors. Similarly, the odds of active T. pallidum infections were significantly higher in African American (OR 15.0, 95% CI 7.0-32.3) and Hispanic (OR = 5.8, 95% CI 2.9-11.6) as compared to Caucasian donors. Syphilis seropositivity was associated with first time blood donation, increasing age, lower education, birth outside the US, and positive tests for HIV and HCV. Geographically, T. pallidum seropositivity was increased in southern and western regions of the US. Given the low seroprevalence of syphilis in blood donors, continued screening remains debatable; however it may provide a public health benefit through surveillance of at-risk populations.
- 23 July 2014
- Published by Wiley in Vox Sanguinis
- Vol. 107 (4) , 333-342
A pilot external quality assurance study of transfusion screening for HIV, HCV and HBsAG in 12 African countries
Background and Objectives: Serologic screening for the major transfusion transmissible viruses (TTV) is critical to blood safety and has been widely implemented. However, actual performance as measured by proficiency testing has not been well studied in sub‐Saharan Africa. Therefore, we conducted an external quality assessment of laboratories engaged in transfusion screening in the region.Materials and Methods: Blinded test panels, each comprising 25 serum samples that were pedigreed for HIV, HBsAg, HCV and negative status, were sent to participating laboratories. The panels were tested using the laboratories' routine donor screening methods and conditions. Sensitivity and specificity were calculated, and multivariable analysis was used to compare performance against mode of testing, country and infrastructure.Results: A total of 12 African countries and 44 laboratories participated in the study. The mean (range) sensitivities for HIV, HBsAg and HCV were 91·9% (14·3–100), 86·7% (42·9–100) and 90·1% (50–100), respectively. Mean specificities for HIV, HBsAg and HCV were 97·7%, 97% and 99·5%, respectively. After adjusting for country and infrastructure, rapid tests had significantly lower sensitivity than enzyme immunoassays for both HBsAg (P < 0·0001) and HCV (P < 0·05). Sensitivity also varied by country and selected infrastructure variables.Conclusion: While specificity was high, sensitivity was more variable and deficient in a substantial number of testing laboratories. These findings underscore the importance of proficiency testing and quality control, particularly in Africa where TTV prevalence is high.
- 23 July 2014
- Published by Wiley in Vox Sanguinis
- Vol. 107 (4) , 333-342
A pilot external quality assurance study of transfusion screening for HIV, HCV and HBsAG in 12 African countries
Background and Objectives: Serologic screening for the major transfusion transmissible viruses (TTV) is critical to blood safety and has been widely implemented. However, actual performance as measured by proficiency testing has not been well studied in sub‐Saharan Africa. Therefore, we conducted an external quality assessment of laboratories engaged in transfusion screening in the region.Materials and Methods: Blinded test panels, each comprising 25 serum samples that were pedigreed for HIV, HBsAg, HCV and negative status, were sent to participating laboratories. The panels were tested using the laboratories' routine donor screening methods and conditions. Sensitivity and specificity were calculated, and multivariable analysis was used to compare performance against mode of testing, country and infrastructure.Results: A total of 12 African countries and 44 laboratories participated in the study. The mean (range) sensitivities for HIV, HBsAg and HCV were 91·9% (14·3–100), 86·7% (42·9–100) and 90·1% (50–100), respectively. Mean specificities for HIV, HBsAg and HCV were 97·7%, 97% and 99·5%, respectively. After adjusting for country and infrastructure, rapid tests had significantly lower sensitivity than enzyme immunoassays for both HBsAg (P < 0·0001) and HCV (P < 0·05). Sensitivity also varied by country and selected infrastructure variables.Conclusion: While specificity was high, sensitivity was more variable and deficient in a substantial number of testing laboratories. These findings underscore the importance of proficiency testing and quality control, particularly in Africa where TTV prevalence is high.
- 16 July 2014
- Published by Wiley in Vox Sanguinis
- Vol. 107 (4) , 428-430
Microchimerism in the transfused obstetric population
Microchimerism (MC), the coexistence of allogeneic populations of cells within a host, is well described in pregnancy and blood transfusion. To date, transfusion‐associated MC (TA‐MC) appears unique to patients transfused after severe traumatic injury. We sought to determine whether transfusion in the peripartum period results in enduring, high‐level TA‐MC. We conducted a prospective cohort study of 22 women who were newly transfused within 48 h of delivery. Two subjects showed evidence of transient TA‐MC; however, MC was not detected at 6 weeks and 6 months. The negative findings suggest that enduring TA‐MC does not occur in this population.
- 16 July 2014
- Published by Wiley in Vox Sanguinis
- Vol. 107 (4) , 428-430
Microchimerism in the transfused obstetric population
Microchimerism (MC), the coexistence of allogeneic populations of cells within a host, is well described in pregnancy and blood transfusion. To date, transfusion‐associated MC (TA‐MC) appears unique to patients transfused after severe traumatic injury. We sought to determine whether transfusion in the peripartum period results in enduring, high‐level TA‐MC. We conducted a prospective cohort study of 22 women who were newly transfused within 48 h of delivery. Two subjects showed evidence of transient TA‐MC; however, MC was not detected at 6 weeks and 6 months. The negative findings suggest that enduring TA‐MC does not occur in this population.
- 30 January 2013
- Published by Wiley in Transfusion
- Vol. 53 (10) , 2299-2306
Development of a real‐time polymerase chain reaction assay for sensitive detection and quantitation of Babesia microti infection
Background: Babesia microti, the most frequently implicated pathogen in transfusion‐transmitted babesiosis, is widely endemic in the Northeast and upper Midwestern United States. High seroprevalence in endemic areas limits antibody‐based donor screening. A high‐performance molecular test is needed to identify donors in the preseroconversion window phase as well as to discriminate past serologic exposure with parasite clearance from continued parasitemia.Study Design and Methods: Frozen Babesia‐spiked whole blood was microcentrifuged, and the supernatant transferred and microcentrifuged again to concentrate the parasite. The DNA was extracted and amplified using real‐time polymerase chain reaction (PCR) using Babesia‐specific primers. The assay was employed in three series of experiments: 1) a validation and optimization spiking experiment, 2) a blinded serial dilution probit analysis to determine the limit of detection, and 3) evaluation of two blinded panels of clinical samples from possible babesiosis cases.Results: At a decreasing inoculum of 445, 44.5, and 4.45 copies/mL, the assay had positive rates of 100, 97.5, and 81%, respectively. The blinded probit analysis demonstrated a detection rate of 95 and 50% at 12.92 and 1.52 parasites/2 mL of whole blood, respectively. Evaluation of clinical samples showed 13 of 21 samples to be positive, with a range of 85 to 4.8 million parasites/mL. There were no positives detected among 48 healthy donorsConclusion: We have developed a highly sensitive and specific, quantitative real‐time PCR‐based assay for detection of B. microti that could have a useful role in blood screening. It can also be employed broadly to understand Babesia epidemiology, disease pathogenesis, and host immunology.
- 30 January 2013
- Published by Wiley in Transfusion
- Vol. 53 (10) , 2299-2306
Development of a real‐time polymerase chain reaction assay for sensitive detection and quantitation of Babesia microti infection
Background: Babesia microti, the most frequently implicated pathogen in transfusion‐transmitted babesiosis, is widely endemic in the Northeast and upper Midwestern United States. High seroprevalence in endemic areas limits antibody‐based donor screening. A high‐performance molecular test is needed to identify donors in the preseroconversion window phase as well as to discriminate past serologic exposure with parasite clearance from continued parasitemia.Study Design and Methods: Frozen Babesia‐spiked whole blood was microcentrifuged, and the supernatant transferred and microcentrifuged again to concentrate the parasite. The DNA was extracted and amplified using real‐time polymerase chain reaction (PCR) using Babesia‐specific primers. The assay was employed in three series of experiments: 1) a validation and optimization spiking experiment, 2) a blinded serial dilution probit analysis to determine the limit of detection, and 3) evaluation of two blinded panels of clinical samples from possible babesiosis cases.Results: At a decreasing inoculum of 445, 44.5, and 4.45 copies/mL, the assay had positive rates of 100, 97.5, and 81%, respectively. The blinded probit analysis demonstrated a detection rate of 95 and 50% at 12.92 and 1.52 parasites/2 mL of whole blood, respectively. Evaluation of clinical samples showed 13 of 21 samples to be positive, with a range of 85 to 4.8 million parasites/mL. There were no positives detected among 48 healthy donorsConclusion: We have developed a highly sensitive and specific, quantitative real‐time PCR‐based assay for detection of B. microti that could have a useful role in blood screening. It can also be employed broadly to understand Babesia epidemiology, disease pathogenesis, and host immunology.
- 1 January 2013
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 27 (1) , 10-20
Transfusion-Associated Microchimerism: The Hybrid Within
- 1 January 2013
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 27 (1) , 10-20
Transfusion-Associated Microchimerism: The Hybrid Within
- 1 April 2012
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 26 (2) , 164-180
Blood Transfusion Safety in Africa: A Literature Review of Infectious Disease and Organizational Challenges
- 1 April 2012
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 26 (2) , 164-180
Blood Transfusion Safety in Africa: A Literature Review of Infectious Disease and Organizational Challenges
- 13 December 2011
- Published by Wiley in Transfusion
- Vol. 52 (7) , 1517-1522
The third described case of transfusion‐transmitted Babesia duncani
BACKGROUND: Almost all of the reported US tick‐borne and transfusion‐associated Babesia cases have been caused by Babesia microti, which is endemic in the Northeast and upper Midwest. We investigated a case caused by B. duncani (formerly, the WA1‐type parasite), in a 59‐year‐old California resident with sickle cell disease (HbSS) whose only risk factor for infection was receipt of red blood cell transfusions.CASE REPORT: The patient's case was diagnosed in September 2008: intraerythrocytic parasites were noted on a blood smear, after a several‐month history of increasing transfusion requirements. Molecular and indirect fluorescent antibody (IFA) analyses were negative for B. microti but were positive for B. duncani (IFA titer, 1:1024). The complete 18S ribosomal RNA gene of the parasite was amplified from a blood specimen; the DNA sequence was identical to the sequence for the index WA1 parasite isolated in 1991. The patient's case prompted a transfusion investigation: 34 of 38 pertinent blood donors were evaluated, none of whom tested positive by B. microti IFA. The implicated donor—a 67‐year‐old California resident—had a B. duncani titer of 1:4096; B. duncani also was isolated by inoculating jirds (Mongolian gerbils) with a blood specimen from March 2009, more than 10 months after his index donation in April 2008. The patient's case was diagnosed more than 4 months after the implicated transfusion in May 2008.CONCLUSIONS: This patient had the third documented transfusion case caused by B. duncani. His case underscores the fact that babesiosis can be caused by agents not detected by molecular or serologic analyses for B. microti.
- 13 December 2011
- Published by Wiley in Transfusion
- Vol. 52 (7) , 1517-1522
The third described case of transfusion‐transmitted Babesia duncani
BACKGROUND: Almost all of the reported US tick‐borne and transfusion‐associated Babesia cases have been caused by Babesia microti, which is endemic in the Northeast and upper Midwest. We investigated a case caused by B. duncani (formerly, the WA1‐type parasite), in a 59‐year‐old California resident with sickle cell disease (HbSS) whose only risk factor for infection was receipt of red blood cell transfusions.CASE REPORT: The patient's case was diagnosed in September 2008: intraerythrocytic parasites were noted on a blood smear, after a several‐month history of increasing transfusion requirements. Molecular and indirect fluorescent antibody (IFA) analyses were negative for B. microti but were positive for B. duncani (IFA titer, 1:1024). The complete 18S ribosomal RNA gene of the parasite was amplified from a blood specimen; the DNA sequence was identical to the sequence for the index WA1 parasite isolated in 1991. The patient's case prompted a transfusion investigation: 34 of 38 pertinent blood donors were evaluated, none of whom tested positive by B. microti IFA. The implicated donor—a 67‐year‐old California resident—had a B. duncani titer of 1:4096; B. duncani also was isolated by inoculating jirds (Mongolian gerbils) with a blood specimen from March 2009, more than 10 months after his index donation in April 2008. The patient's case was diagnosed more than 4 months after the implicated transfusion in May 2008.CONCLUSIONS: This patient had the third documented transfusion case caused by B. duncani. His case underscores the fact that babesiosis can be caused by agents not detected by molecular or serologic analyses for B. microti.
- Open Access
- 1 January 2011
- Vol. 2 (1) , 6-10
Male microchimerism in peripheral blood leukocytes from women with multiple sclerosis
Fetal microchimerism (F-MC), the persistence of fetal cells in the mother, is frequently encountered following pregnancy. The high prevalence of F-MC in autoimmune disease prompts consideration of the role for immune tolerance and regulation. This study examines the association between F-MC and multiple sclerosis (MS), an autoimmune disorder, of undetermined etiology. 21 out of 51 MS-positive subjects (41%) were classified as positive for F-MC; 4 of 22 (18%) of MS-negative sibling controls, were also positive for MC (p = 0.066). Unanticipated F-MC in controls lead to re-evaluation using 30 female singleton cord blood units (CBUs) as a biological control. Four CBUs were low-level positive. Seventy-three female subjects were assigned to three groups according to disease status and pregnancy history: (1) MS positive (+) women with a history of one male pregnancy before symptom onset (n = 27); (2) MS negative (−) female siblings of MS+ women with a history of one male pregnancy (n = 22); and (3) MS+ women that reported never having been pregnant (n = 24). Ten micrograms of genomic DNA obtained from peripheral blood leukocytes of each subject were analyzed for F-MC using allele-specific real-time PCR targeting the SR-Y sequence on the Y-chromosome. MC classification was dichotomous (positive vs. negative) based on PCR results. The association between F-MC and MS warrants further study to define this relationship. F-MC in women self-reporting as nulligravid, supports previous findings that a significant proportion of pregnancies go undetected. This lead to re-validation of a Y-chromosome based assay for F-MC detection.
- 1 January 2011
- Vol. 2 (1) , 6-10
Open AccessMale microchimerism in peripheral blood leukocytes from women with multiple sclerosis
Fetal microchimerism (F-MC), the persistence of fetal cells in the mother, is frequently encountered following pregnancy. The high prevalence of F-MC in autoimmune disease prompts consideration of the role for immune tolerance and regulation. This study examines the association between F-MC and multiple sclerosis (MS), an autoimmune disorder, of undetermined etiology. 21 out of 51 MS-positive subjects (41%) were classified as positive for F-MC; 4 of 22 (18%) of MS-negative sibling controls, were also positive for MC (p = 0.066). Unanticipated F-MC in controls lead to re-evaluation using 30 female singleton cord blood units (CBUs) as a biological control. Four CBUs were low-level positive. Seventy-three female subjects were assigned to three groups according to disease status and pregnancy history: (1) MS positive (+) women with a history of one male pregnancy before symptom onset (n = 27); (2) MS negative (−) female siblings of MS+ women with a history of one male pregnancy (n = 22); and (3) MS+ women that reported never having been pregnant (n = 24). Ten micrograms of genomic DNA obtained from peripheral blood leukocytes of each subject were analyzed for F-MC using allele-specific real-time PCR targeting the SR-Y sequence on the Y-chromosome. MC classification was dichotomous (positive vs. negative) based on PCR results. The association between F-MC and MS warrants further study to define this relationship. F-MC in women self-reporting as nulligravid, supports previous findings that a significant proportion of pregnancies go undetected. This lead to re-validation of a Y-chromosome based assay for F-MC detection.